Read on Twitter
Is the #OncotypeDX recurrence score (RS) the best measure for #lobular #breastcancer? This retrospective analysis in @ACS_Research Journals suggests NO. 1/6 #bcsm @oncoalert @practiceupdate @medscape @elbcc @oesterreich @metzger https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.33104
Results show that #lobular #breastcancer is associated with a low and medium Recurrence Score. BUT despite lower scores, 5‐year DFS is similar to that of nonlobular #BC. What is happening that makes #oncotypeDX a less effective predictor for lobular? @MeganKruseMD @mjsikora 2/6
#Lobularbreastcancer has different molecular traits, metastatic pattern, clinical presentation. #lobular tumors in this study had a higher tumor classification, higher lymph node status, lower grade, lower Ki67 index, and low/int RS. 3/6 @jackel626 https://bit.ly/2EQJXTr
Despite clear differences and poorer longer-term survival https://bit.ly/2EILxXx #lobular #breastcancer is treated the same as #ductal. For #ILC risk assessment, authors propose the RS be COMPLEMENTED BY CLINICOPATHOLOGIC PARAMETERS FOR THERAPY DECISION MAKING. 4/6
Related, researchers out of Australia published a #lobular specific RS option they named #LobSig, a multi-gene predictor specifically for #lobularbreastcancer. Can this be developed to see if it is better RS for predicting #ILC outcomes? @amymccart 5/6 https://www.nature.com/articles/s41523-019-0113-y
Patients living with #lobular #breastcancer need tools and therapies that consider the differences in our disease, to get best outcomes. Pls include #lobularbreastcancer in your research. #notallbreastcanceristhesame 6/6 #bcsm @double_whammied @lpseattle https://lobularbreastcancer.org/
